EPIRUS Biopharmaceuticals expands biosimilar pipeline and capabilities with acquisition

EPIRUS Biopharmaceuticals, Inc. has announced an agreement for the acquisition of Bioceros Holding B.V enabling EPIRUS to expand its biosimilar pipeline and vertically integrate product development capabilities.

From the Bioceros platform, EPIRUS will expand its pipeline with the addition of three preclinical product candidates: BOW080, a proposed biosimilar to eculizumab; BOW090, a proposed biosimilar to ustekinumab, and BOW100, a proposed biosimilar to goluimnab.

These three new pipeline assets represent a global growth opportunity for EPIRUS in targeting biologics with esteimated 2020 peak sales of $12 billion. The platform also enables future pipeline growth opportunities for the company.

“Building a focussed, sustainable and profitable biosimilar business requires capabilities for efficient pipeline growth. With this in mind, we are excited to welcome Bioceros and their world-class capabilities and expertise,” says Amit Munshi (pictured) President and CEO of EPIRUS. “Together, we will continue working to improve patient access to important, cost-effective medicines worldwide. Our combined biosimilar pipeline targets biologics with sales of $29 billion, which we estimate to be a biosimilar market opportunity of more than $9 billion.”

Bram Bout, Ph.D., CEO and Chairman of the management board, Bioceros, adds: “Having worked with Epirus as a partner over the last several years, we believe stringing in the Company’s vision and their ability to execute. With our proven track record, our team brings substantial cell line and process development experience, representing a strong asset for Epirus.”

Bioceros is a privately-held, Netherlands-based biopharmaceutical R&D company focussed on the development of biosimilar monoclonal antibodies (mAbs) and generation of GMP-ready vell lines. Over the past decade, the company has developed numerous biosimilar cell lines from its proprietary, well-characterised CHO platform. Its staff of scientists, fully-equipped labs and bioreactor capabilities have been designed for the development of mAbs and protein therapeutics, with a focus of biosimilars.

Based on materials supplied by EPIRUS Biopharmaceuticals.